A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patientsResearch in context

MLA

Yuji Hiromatsu, et al. “A Randomised, Double-Masked, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Teprotumumab for Active Thyroid Eye Disease in Japanese PatientsResearch in Context.” The Lancet Regional Health. Western Pacific, vol. 55, no. 101464-, Feb. 2025. EBSCOhost, https://doi.org/10.1016/j.lanwpc.2025.101464.

APA

Yuji Hiromatsu, Eri Ishikawa, Ai Kozaki, Yasuhiro Takahashi, Mika Tanabe, Ken Hayashi, Yukihiro Imagawa, Kazutoyo Kaneda, Masashi Mimura, Xiaoxian Dai, Tomoko Hayashida, & Takashi Akamizu. (2025). A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patientsResearch in context. The Lancet Regional Health. Western Pacific, 55(101464-). https://doi.org/10.1016/j.lanwpc.2025.101464

Chicago

Yuji Hiromatsu, Eri Ishikawa, Ai Kozaki, Yasuhiro Takahashi, Mika Tanabe, Ken Hayashi, Yukihiro Imagawa, et al. 2025. “A Randomised, Double-Masked, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Teprotumumab for Active Thyroid Eye Disease in Japanese PatientsResearch in Context.” The Lancet Regional Health. Western Pacific 55 (101464-). doi:10.1016/j.lanwpc.2025.101464.